Cubist Pharmaceuticals (CBST) Q2 2012 Earnings Call July 19, 2012 5:00 pm ET Executives Eileen C. McIntyre - Senior Director of Investor Relations Michael W. Bonney - Chief Executive Officer and Director David W. J. McGirr - Chief Financial Officer, Principal Accounting Officer and Senior Vice President Robert J. Perez - President and Chief Operating Officer Steven C. Gilman - Chief Scientific Officer and Executive Vice President of Research & Development Gregory Stea - Senior Vice President of Commercial Operations Analysts Mario V. Corso - Caris & Company, Inc., Research Division Thomas J. Russo - Robert W. Baird & Co. Incorporated, Research Division Eun K. Yang - Jefferies & Company, Inc., Research Division Steve Byrne - BofA Merrill Lynch, Research Division Alan Carr - Needham & Company, LLC, Research Division Adnan S. Butt - RBC Capital Markets, LLC, Research Division James F. Molloy - ThinkEquity LLC, Research Division Howard Liang - Leerink Swann LLC, Research Division Stephen Willey - Stifel, Nicolaus & Co., Inc., Research Division PresentationOperator
Good day. My name is Nikki, and I will be your events specialist today. At this time, I would like to welcome everyone to the Cubist Pharmaceuticals Second Quarter Earnings Call. [Operator Instructions] At this time, I would like to turn today's program over to Eileen McIntyre. Eileen, you may begin. Eileen C. McIntyre Good afternoon, and thank you for joining us for our review of Second Quarter 2012 Business Performance and Financial Results of Cubist Pharmaceuticals. Before introducing our speakers, I will read the safe harbor statement and describe the context for use of non-GAAP financial measures.